Science

Feb 28, 2025, 14:37

Yan Leyfman: Promising Results for Sickle Cell Transplant

Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Adetola A. Kassim, et al. on LinkedIn:

“Promising Results for Sickle Cell Transplant!

A new study shows HLA-haploidentical bone marrow transplantation (BMT) with post-transplant cyclophosphamide may be a curative option for adults with sickle cell disease.

88% event-free survival at 2 years.
95% overall survival.
Low rates of severe GVHD (4.8%).
Challenges remain: infections & graft failure.

These findings support BMT as a viable therapy, but risks must be carefully managed.”

Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.

Authors: Adetola A. Kassim, et al.

Yan Leyfman: Promising Results for Sickle Cell Transplant

Adetola A. Kassim BMT Bone Marrow Transplantation cancer Cyclophosphamide fight against cancer Global fight against cancer MedNews Week OncoDaily Oncology Sickle Cell Transplant Yan Leyfman

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more